ALS Association Starts Disaster Relief Fund for Patients Affected by Hurricane Harvey
The ALS Association has established a disaster relief fund to help patients and their families who were affected by…
Articles by Margarida Azevedo, MSc
ALS Association Celebrates 3rd Anniversary of ALS Ice Bucket Challenge with New Campaign
The ALS Association is celebrating the third anniversary of the ALS Ice Bucket Challenge with a new awareness…
BrainStorm Appoints VP of Patient Advocacy and Government Affairs
BrainStorm Cell Therapeutics has appointed a new vice president of patient advocacy and government affairs, a move intended to reinforce…
Amylyx Pharmaceuticals Doses First Patient in Phase 2 Trial of AMX0035 as an ALS Therapy
Amylyx Pharmaceuticals has dosed the first patient in a Phase 2 clinical trial that will assess AMX0035’s ability to treat…
Southern Research Names New Neuroscience Chair to Expand Fight Against ALS, Other Diseases
Alabama-based Southern Research has appointed neurodegenerative diseases expert Rita Cowell as chair of its neuroscience department to help expand research into…
Maker of Radicava, MT Pharma America, Changes Name to Mitsubishi Tanabe Pharma America
MT Pharma America, maker of Radicava (edaravone), an intravenous treatment for adults with amyotrophic lateral sclerosis (ALS), has changed…
Kate Farms Launches High-calorie Peptide Tube Feeding Formula for ALS, Other Conditions
Kate Farms, a company that develops plant-based oral and tube feeding formulas, has launched its Core Essentials Peptide…
UC Irvine Medical Center to Take Part in Phase 3 NurOwn Trial for ALS
BrainStorm Cell Therapeutics has signed an agreement with the University of California Irvine Medical Center (UCI) to start…
As Radicava Availability Nears, Healthcare Providers Can Start Patient Insurance Benefits Process
Healthcare providers may now begin researching the insurance benefits process for patients in advance of the upcoming availability of…
Cytokinetics Launches Phase 2 Clinical Trial of Therapy Candidate CK-2127107 for ALS
Cytokinetics recently announced the start of a Phase 2 clinical trial investigating a…